Editorial Board About Us

Michael K Brawer

All articles from this author are listed below.

Volume 7, Supplement 7 Review Articles

Recent Developments in the Metabolic Management of BPH

Michael K Brawer

Volume 7, Supplement 3 Review Articles

Prostatic Intraepithelial Neoplasia: An Overview

Michael K Brawer

Prostate cancer Androgen deprivation therapy Biopsy Chemoprevention Repeat biopsy Prostatic intraepithelial neoplasia (PIN)High-grade PIN Epidemiology

Volume 8, Number 3 Meeting Reviews

Best of the 2006 AUA Annual Meeting

Meeting Review

Claus G Roehrborn Michael K Brawer Arie S Belldegrun John P Stein John P Mulhall Tobias Klatte Michael E Aldridge Li-Ming Su Shachi Tyagi Danil V Makarov Ellen Shapiro Alan W Partin Michael B Chancellor Victor W Nitti J Curtis Nickel Jacob Rajfer

Highlights from the 2006 Annual Meeting of the American Urological Association May 20–25, 2006 Atlanta, GA

Prostate cancer Infertility Benign prostatic hyperplasia Bladder cancer Kidney cancer Lower urinary tract symptoms Bladder exstrophy Overactive bladder Interstitial cystitis Stress urinary incontinence Peyronie’s disease Spina bifida Neurogenic bladder Erectile dysfunction Chronic pelvic pain syndrome Chronic prostatitis Tumor markers Androgen replacement therapy Ejaculatory dysfunction Anorectal malformations Renal stones Robotic-assisted radical prostatectomy

Volume 8, Supplement 2 Review Articles

16th International Prostate Cancer Update

Introduction

Michael K Brawer

Volume 8, Supplement 2 Review Articles

Hormonal Therapy for Prostate Cancer

16th International Prostate Cancer Update

Michael K Brawer

Updates on hormonal therapy in the treatment of prostate cancer are presented. The most common therapy is to reduce testosterone to castrate levels. A dosage of 1 mg diethylstilbestrol daily prolonged survival in patients with advanced prostate cancer. The leuteinizing hormone–releasing hormone agonists have essentially replaced surgical orchiectomy in the vast majority of clinical settings; however, a major problem with the leuteinizing hormone– releasing hormone agonists has been the surge and flare of testosterone levels. If hormonal therapy is initiated early, the risk of major complications is significantly decreased. Combined androgen blockade is better than monotherapy, although there is only a small clinical benefit. When androgen deprivation is used for a short time and the normal androgen milieu is re-established, the side effects and toxicity of androgen deprivation are decreased. The major complications of androgen deprivation include hot flushes, reduction of bone mineral density, osteoporosis, and anemia. Intermittent androgen blockade might have the same benefits of total androgen suppression with fewer side effects, increased duration of androgen dependence, and less cost. The 10 steps to take when advising patients about initiation of androgen deprivation therapy are reviewed. [Rev Urol. 2006;8(suppl 2):S35-S47]

Prostate cancer Hormonal therapy Androgen ablation Diethylstilbestrol

Volume 9, Number 3 Meeting Reviews

Best of the 2007 AUA Annual Meeting

Meeting Review

Claus G Roehrborn Michael K Brawer Dean G Assimos Danil V Makarov Ellen Shapiro Alan W Partin Michael B Chancellor J Curtis Nickel Jacob Rajfer

Highlights from the 2007 Annual Meeting of the American Urological Association May 19-24, 2007 Anaheim, CA [Rev Urol. 2007;9(3):133-154]

Prostate cancer Obesity Benign prostatic hyperplasia Antibiotic prophylaxis Nocturia Lower urinary tract symptoms Botulinum toxin Prostate-specific antigen Biomarkers PCA3 Testosterone Urinary tract infections Urolithiasis Laser ablation Endourology Male voiding dysfunction LHRH antagonists Antimuscarinic agents Circumcision Repeat biopsy Human glandularkallikrein Expectant management CRISP-3 MSP Microvesseldensity Endoglin Survivin Telomeres Interleukin-8 PDE-5 inhibitors Acute urinaryretention 5Alpha-reductase inhibitors Doxazosin Finasteride Transurethral microwave thermotherapy TURP Perioperative blood loss Microbialbiofilms HIV Stem cell injection

Volume 9, Number 1 Review Articles

Recent Progress in the Treatment of Advanced Prostate Cancer With Intermittent Dose-Intense Calcitriol (DN-101)

Treatment Update

Michael K Brawer

Docetaxel is becoming standard therapy for androgen-independent prostate cancer (AIPC), and investigational agents are being added to docetaxel to assess potential additive effects and synergy. Although one of these agents, calcitriol, has repeatedly demonstrated antiproliferative properties against cancer of the prostate, breast, colon, and lung, the antineoplastic activity of calcitriol requires superphysiologic levels. Unfortunately, chronic exposure to superphysiologic levels of calcitriol causes hypercalcemia and resulting toxicity. Therefore, a host of analogues of calcitriol have been investigated for antineoplastic function, including intermittent dose-intense calcitriol, or DN-101. Because of encouraging results from phase II studies of DN-101 combined with docetaxel, the ASCENT (AIPC Study of Calcitriol Enhancement of Taxotere) phase II trial investigated docetaxel plus DN-101 versus docetaxel plus placebo in 250 men with metastatic AIPC and an abnormal baseline prostate-specific antigen (PSA) level. Although the ASCENT trial did not achieve its primary endpoint for increased PSA response, there was a significant trend in PSA response rate in the DN-101 arm. DN-101 in combination with docetaxel seems to improve overall survival and, interestingly, has a favorable safety profile compared with docetaxel alone. The DN-101/docetaxel combination is currently being studied in a much larger international trial, ASCENT-2. [Rev Urol. 2007;9(1):1-8]

Prostate cancer Vitamin D Calcitriol DN-101 Docetaxel

Volume 10, Number 4 Meeting Reviews

New Treatments for Castration-Resistant Prostate Cancer

Meeting Review

Michael K Brawer

Highlights from the 44th Annual Meeting of the American Society of Clinical Oncology, May 30–June 3, 2008, Chicago, IL [Rev Urol. 2008;10(4):294-296]

Prostate cancer, castration-resistant Abiraterone MDV3100

Volume 11, Number 2 Meeting Reviews

Best of the 2009 AUA Annual Meeting

Highlights From the 2009 Annual Meeting of the American Urological Association, April 25-30, 2009, Chicago, IL

Naoki Yoshimura Michael K Brawer Arie S Belldegrun B Shuch F Pouliot Michael B Chancellor Ellen Shapiro Alan W Partin Dean G Assimos Stacy Loeb J Curtis Nickel Claus G Roehrborn

Prostate cancer screening Obesity Benign prostatic hyperplasia Lower urinary tract symptoms Vesicoureteral reflux Nephrolithiasis Stress urinary incontinence Inflammation Silodosin Hormonal therapy Tumor markers TMPRSS2ERG 4-Kallikrein panel Botulinum toxin type A Male voiding dysfunction Benign prostatic specific antigen Roux-en-Y gastric bypass surgery Genitourinary pain index UPOINT clinical phenotype system Nephron-sparing surgery Watchful waiting Laparoscopy for adrenal cortical carcinoma Partial adrenalectomy Urethral trauma Pediatric urethral stricture Enteric urologic surgery